NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT05456191 2026-02-06
ASC4START
Novartis
Phase 3 Active not recruiting
NCT03509896 2022-06-27
Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Bristol-Myers Squibb
Completed
NCT00171223 2021-07-22
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
Novartis
Phase 2 Completed
NCT00171249 2021-07-22
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
Novartis
Phase 2 Completed
NCT00171158 2021-06-25
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Novartis
Phase 2 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT00261846 2017-07-27
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Pfizer
Phase 2 Completed
NCT01061177 2017-02-24
'MACS1252
Novartis
Phase 4 Completed
NCT00420043 2016-04-05
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
Novartis
Phase 1 Completed
NCT00422825 2016-04-05
Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib
Novartis
Phase 1 Completed
NCT01254188 2016-03-03
ENESTxtnd
Novartis
Phase 3 Completed
NCT01511289 2016-02-24
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Il-Yang Pharm. Co., Ltd.
Phase 3 Completed